OKYO Pharma to Present at BIO-Europe 2025 in Vienna
MWN-AI** Summary
OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, is poised to present significant updates at the 33rd Annual BIO-Europe partnering conference in Vienna, Austria, from November 3-5, 2025. CEO Gary S. Jacob, Ph.D., will highlight the company's lead investigational candidate, urcosimod, and share insights from a recently completed Phase 2 clinical trial targeting NCP, a severe ocular condition lacking FDA-approved therapies.
NCP is characterized by debilitating pain and sensitivity in the eyes, face, or head, often resulting from nerve damage combined with inflammation. Current treatment options are limited and primarily involve off-label use of various topical and systemic medications. Urcosimod, formerly known as OK-101, is positioned as a promising solution, being a lipid-conjugated chemerin peptide agonist designed to mitigate inflammation and pain linked to ocular disorders.
Dr. Jacob expressed enthusiasm about participating in BIO-Europe, emphasizing the event's importance as a venue for fostering partnerships within the biopharma sector. He noted the opportunity to engage potential collaborators and global leaders as OKYO continues to advance urcosimod through its clinical development. The management team plans to partake in one-on-one meetings to discuss clinical milestones, including the positive data from both urcosimod trials for treating dry eye disease and NCP.
OKYO Pharma aims to redefine treatment approaches for eye-related conditions through ongoing research and the development of novel molecules, striving to meet the critical unmet needs in ocular health. For more details on OKYO Pharma and its innovations, please visit their website at www.okyopharma.com.
MWN-AI** Analysis
OKYO Pharma Limited (NASDAQ: OKYO) is steadily positioning itself as a key player in the biopharmaceutical industry, particularly in the field of ophthalmology, with its innovative approach to treating neuropathic corneal pain (NCP) and dry eye disease. The company’s upcoming presentation at the BIO-Europe 2025 conference in Vienna, scheduled for November 3-5, 2025, presents a prime opportunity for market players and investors to evaluate its progress and future potential.
Dr. Gary S. Jacob's presentation will focus on urcosimod, a promising candidate that has shown significant efficacy in recent clinical trials. The completion of a Phase 2 trial for NCP, a highly debilitating condition with no FDA-approved treatment, is particularly noteworthy. This positions OKYO at the forefront of addressing a crucial unmet medical need, potentially attracting strategic partnerships and collaborations highlighted during the conference.
Investors should closely monitor the developments surrounding urcosimod, as clear statistical significance in Phase 2 trials suggests it may be a game-changer in the treatment landscape. The innovative lipid conjugated chemerin peptide mechanism of action indicates potential advantages in both efficacy and tolerability, which may facilitate expedited clinical development.
As the global biopharmaceutical market continues to grow, driven by increasing demand for novel therapies, OKYO’s focus on niche areas like NCP could present substantial upside. Engaging in one-on-one meetings with industry leaders at BIO-Europe can further enhance its visibility, potentially driving partnership opportunities that could lead to funding or distribution agreements.
In conclusion, for investors looking to capitalize on emerging biotech opportunities, keeping an eye on OKYO Pharma's progress at BIO-Europe is advisable, as successful partnerships or advancements in clinical trials could bolster the company's market standing significantly.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LONDON and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO Pharma, will present at the 33rd Annual BIO-Europe partnering conference in Vienna, Austria.
BIO-Europe, one of the largest and most impactful international life science partnering events, is scheduled for November 3-5, 2025, at the Vienna Congress and Convention Center, Vienna. Dr. Jacob's presentation will highlight OKYO's lead investigational candidate, urcosimod, and provide updates on the company's recently completed Phase 2 clinical trial for the treatment of NCP.
"We are excited to showcase our progress at BIO-Europe, a premier platform for advancing partnerships in the biopharma sector," said Gary S. Jacob, Ph.D., CEO of OKYO Pharma. "This event offers a unique opportunity to engage with global leaders and potential collaborators as we advance urcosimod toward addressing critical unmet needs in ocular diseases."
In addition to the presentation, the OKYO management team will participate in one-on-one partnering meetings to discuss clinical milestones, including recent positive clinical data for urcosimod and the acceleration of its clinical development program.
About Neuropathic Corneal Pain (NCP)
NCP is a condition that causes severe pain and sensitivity of the eyes, face, or head. The exact cause of NCP is unknown but is thought to result from nerve damage to the cornea combined with inflammation . NCP, which can exhibit as a severe, chronic, debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated, with limited success, by various topical and systemic treatments in an off-label fashion.
About Urcosimod (formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the residence time of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a 240-patient Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and is presently being evaluated in a just-completed randomized, placebo-controlled, double-masked Phase 2 trial involving 17 neuropathic corneal pain patients.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and ocular diseases. In addition to the completed Phase 2 trial of urcosimod to treat dry eye disease patients, OKYO is also currently evaluating urcosimod to treat neuropathic corneal pain patients, and recently completed a Phase 2 trial.
For further information, please visit www.okyopharma.com .
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | +44 (0)20 7495 2379 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ**
How will the presentation by Gary S. Jacob, Ph.D., at the BIO-Europe conference impact investor perception of OKYO Pharma Limited OKYO in the competitive biopharma landscape?
What partnerships or collaborations does OKYO Pharma Limited OKYO seek to establish at the BIO-Europe event to advance their drug candidate, urcosimod?
Considering the recent positive clinical data for urcosimod, how does OKYO Pharma Limited OKYO plan to leverage this information to attract investment and support future trials?
What are the next steps for OKYO Pharma Limited OKYO following the recently completed Phase 2 trial for neuropathic corneal pain, and how might these impact the company’s valuation?
**MWN-AI FAQ is based on asking OpenAI questions about OKYO Pharma Limited (NASDAQ: OKYO).
NASDAQ: OKYO
OKYO Trading
2.15% G/L:
$1.66 Last:
147,738 Volume:
$1.65 Open:
